Budesonide and formoterol reduce early innate anti-viral immune responses In Vitro

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Davies, Janet M ^a   Carroll, Melanie L ^a   Li, Hongzhuo ^a   Poh, Alisa M ^a   Kirkegard, Darren ^a   Towers, Michelle ^a,b   Upham, John W ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; ALPHA INTERFERON; BUDESONIDE; CORTICOSTEROID; FLUTICASONE; FORMOTEROL; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMIQUIMOD; INTERLEUKIN 6; PROTEIN A; SALMETEROL; VIRUS ANTIBODY; AMINOQUINOLINE DERIVATIVE; BRONCHODILATING AGENT; CXCL10 PROTEIN, HUMAN; ETHANOLAMINE DERIVATIVE; IMMUNOLOGICAL ADJUVANT; TLR7 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 7;

ADULT; ANTIBODY RESPONSE; ARTICLE; ASTHMA; CELL STIMULATION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; INNATE IMMUNITY; LIVING DONOR; MALE; MYXOVIRUS A; NONHUMAN; ORTHOMYXOVIRUS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RHINOVIRUS; RHINOVIRUS 16; VIRUS GENE; CELL CULTURE; DOSE RESPONSE; DRUG INTERACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; PATHOLOGY; VIROLOGY;

ORTHOMYXOVIRIDAE; RHINOVIRUS;

ADJUVANTS, IMMUNOLOGIC; ADULT; AMINOQUINOLINES; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; CELLS, CULTURED; CHEMOKINE CXCL10; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ETHANOLAMINES; FEMALE; HUMANS; IMMUNITY, INNATE; INTERFERON-ALPHA; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; RHINOVIRUS; TOLL-LIKE RECEPTOR 7;

EID: 81355136055     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027898     Document Type: Article

References (48)

1. Masoli M, Fabian D, Holt S, Beasley R, (2004) The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 59: 469-478.
2. Weiss KB, Sullivan SD, (2001) The health economics of asthma and rhinitis. I. Assessing the economic impact. J Allergy Clin Immunol 107: 3-8.
3. Holgate ST, (2005) Exacerbations: the asthma paradox. Am J Respir Crit Care Med 172: 941-943.
4. Papadopoulos N, Christodoulou I, Rohde G, Agache I, Almqvist C, et al. (2011) Viruses and bacteria in acute asthma exacerbations - A GA2LEN-DARE* systematic review. Allergy 66: 458-468.
5. Nicholson KG, Kent J, Ireland DC, (1993) Respiratory viruses and exacerbations of asthma in adults. BMJ 307: 982-986.
6. Lemanske RF Jr, Dick EC, Swenson CA, Vrtis RF, Busse WW, (1989) Rhinovirus upper respiratory infection increases airway hyperreactivity and late asthmatic reactions. J Clin Invest 83: 1-10.
7. Kusel MM, de Klerk NH, Kebadze T, Vohma V, Holt PG, et al. (2007) Early-life respiratory viral infections, atopic sensitization, and risk of subsequent development of persistent asthma. J Allergy Clin Immunol 119: 1105-1110.
8. Johnston SL, Pattemore PK, Sanderson G, Smith S, Lampe F, et al. (1995) Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ 310: 1225-1229.
9. Cates CJ, Lasserson TJ, (2009) Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children. Cochrane Database Syst Rev pp. CD007313.
10. Buhl R, Vogelmeier C, (2007) Budesonide/formoterol maintenance and reliever therapy: a new treatment approach for adult patients with asthma. Curr Med Res Opin 23: 1867-1878.
11. Chapman KR, Barnes NC, Greening AP, Jones PW, Pedersen S, (2010) Single maintenance and reliever therapy (SMART) of asthma: a critical appraisal. Thorax 65: 747-752.
12. Papadopoulos NG, Stanciu LA, Papi A, Holgate ST, Johnston SL, (2002) A defective type 1 response to rhinovirus in atopic asthma. Thorax 57: 328-332.
13. Papadopoulos NG, Stanciu LA, Papi A, Holgate ST, Johnston SL, (2002) Rhinovirus-induced alterations on peripheral blood mononuclear cell phenotype and costimulatory molecule expression in normal and atopic asthmatic subjects. Clin Exp Allergy 32: 537-542.
14. Kohlmeier JE, Cookenham T, Roberts AD, Miller SC, Woodland DL, (2010) Type I interferons regulate cytolytic activity of memory CD8(+) T cells in the lung airways during respiratory virus challenge. Immunity 33: 96-105.
15. Message SD, Johnston SL, (2004) Host defense function of the airway epithelium in health and disease: clinical background. J Leukoc Biol 75: 5-17.
16. Denburg JA, Sehmi R, Saito H, Pil-Seob J, Inman MD, et al. (2000) Systemic aspects of allergic disease: bone marrow responses. J Allergy Clin Immunol 106: S242-246.
17. Holt PG, Sly PD, (2011) Interaction between adaptive and innate immune pathways in the pathogenesis of atopic asthma: operation of a lung/bone marrow axis. Chest 139: 1165-1171.
18. Subrata LS, Bizzintino J, Mamessier E, Bosco A, McKenna KL, et al. (2009) Interactions between innate antiviral and atopic immunoinflammatory pathways precipitate and sustain asthma exacerbations in children. J Immunol 183: 2793-2800.
19. Bufe A, Gehlhar K, Grage-Griebenow E, Ernst M, (2002) Atopic phenotype in children is associated with decreased virus-induced interferon-alpha release. Int Arch Allergy Immunol 127: 82-88.
20. Gehlhar K, Bilitewski C, Reinitz-Rademacher K, Rohde G, Bufe A, (2006) Impaired virus-induced interferon-alpha2 release in adult asthmatic patients. Clin Exp Allergy 36: 331-337.
21. Roponen M, Yerkovich ST, Hollams E, Sly PD, Holt PG, et al. (2010) Toll-like receptor 7 function is reduced in adolescents with asthma. Eur Respir J 35: 64-71.
22. Parry DE, Busse WW, Sukow KA, Dick CR, Swenson C, et al. (2000) Rhinovirus-induced PBMC responses and outcome of experimental infection in allergic subjects. J Allergy Clin Immunol 105: 692-698.
23. Message SD, Laza-Stanca V, Mallia P, Parker HL, Zhu J, et al. (2008) Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production. Proc Natl Acad Sci U S A 105: 13562-13567.
24. Brooks GD, Buchta KA, Swenson CA, Gern JE, Busse WW, (2003) Rhinovirus-induced interferon-gamma and airway responsiveness in asthma. Am J Respir Crit Care Med 168: 1091-1094.
25. Skevaki CL, Christodoulou I, Spyridaki IS, Tiniakou I, Georgiou V, et al. (2009) Budesonide and formoterol inhibit inflammatory mediator production by bronchial epithelial cells infected with rhinovirus. Clin Exp Allergy 39: 1700-1710.
26. Edwards MR, Haas J, Panettieri RA Jr, Johnson M, Johnston SL, (2007) Corticosteroids and beta2 agonists differentially regulate rhinovirus-induced interleukin-6 via distinct Cis-acting elements. J Biol Chem 282: 15366-15375.
27. Kaur M, Chivers JE, Giembycz MA, Newton R, (2008) Long-acting beta2-adrenoceptor agonists synergistically enhance glucocorticoid-dependent transcription in human airway epithelial and smooth muscle cells. Mol Pharmacol 73: 203-214.
28. Contoli M, Message SD, Laza-Stanca V, Edwards MR, Wark PA, et al. (2006) Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med 12: 1023-1026.
29. Sanders SP, Kim J, Connolly KR, Porter JD, Siekierski ES, et al. (2001) Nitric oxide inhibits rhinovirus-induced granulocyte macrophage colony-stimulating factor production in bronchial epithelial cells. Am J Respir Cell Mol Biol 24: 317-325.
30. Subauste MC, Jacoby DB, Richards SM, Proud D, (1995) Infection of a human respiratory epithelial cell line with rhinovirus. Induction of cytokine release and modulation of susceptibility to infection by cytokine exposure. J Clin Invest 96: 549-557.
31. Carroll ML, Yerkovich ST, Pritchard AL, Davies JM, Upham JW, (2010) Adaptive immunity to rhinoviruses: sex and age matter. Respir Res 11: 184.
32. Pfaffl MW, (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.
33. McCormack PL, Lyseng-Williamson KA, (2007) Budesonide/formoterol: a review of its use as maintenance and reliever inhalation therapy in asthma. Drugs 67: 2407-2431.
34. Edwards MR, Johnson MW, Johnston SL, (2006) Combination therapy: Synergistic suppression of virus-induced chemokines in airway epithelial cells. Am J Respir Cell Mol Biol 34: 616-624.
35. Pang L, Knox AJ, (2000) Synergistic inhibition by beta(2)-agonists and corticosteroids on tumor necrosis factor-alpha-induced interleukin-8 release from cultured human airway smooth-muscle cells. Am J Respir Cell Mol Biol 23: 79-85.
36. Roth M, Johnson PR, Rudiger JJ, King GG, Ge Q, et al. (2002) Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 360: 1293-1299.
37. Todorova L, Gurcan E, Miller-Larsson A, Westergren-Thorsson G, (2006) Lung fibroblast proteoglycan production induced by serum is inhibited by budesonide and formoterol. Am J Respir Cell Mol Biol 34: 92-100.
38. Hung CH, Chu YT, Hua YM, Hsu SH, Lin CS, et al. (2008) Effects of formoterol and salmeterol on the production of Th1- and Th2-related chemokines by monocytes and bronchial epithelial cells. Eur Respir J 31: 1313-1321.
39. van Elden LJ, Sachs AP, van Loon AM, Haarman M, van de Vijver DA, et al. (2008) Enhanced severity of virus associated lower respiratory tract disease in asthma patients may not be associated with delayed viral clearance and increased viral load in the upper respiratory tract. J Clin Virol 41: 116-121.
40. Corne JM, Marshall C, Smith S, Schreiber J, Sanderson G, et al. (2002) Frequency, severity, and duration of rhinovirus infections in asthmatic and non-asthmatic individuals: a longitudinal cohort study. Lancet 359: 831-834.
41. Grunberg K, Sharon RF, Sont JK, In 't Veen JC, Van Schadewijk WA, et al. (2001) Rhinovirus-induced airway inflammation in asthma: effect of treatment with inhaled corticosteroids before and during experimental infection. Am J Respir Crit Care Med 164: 1816-1822.
42. Wark PA, Bucchieri F, Johnston SL, Gibson PG, Hamilton L, et al. (2007) IFN-gamma-induced protein 10 is a novel biomarker of rhinovirus-induced asthma exacerbations. J Allergy Clin Immunol 120: 586-593.
43. Wark PA, Johnston SL, Bucchieri F, Powell R, Puddicombe S, et al. (2005) Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med 201: 937-947.
44. Wark PA, Grissell T, Davies B, See H, Gibson PG, (2009) Diversity in the bronchial epithelial cell response to infection with different rhinovirus strains. Respirology 14: 180-186.
45. Gibson SJ, Lindh JM, Riter TR, Gleason RM, Rogers LM, et al. (2002) Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol 218: 74-86.
46. Upham JW, Zhang G, Rate A, Yerkovich ST, Kusel M, et al. (2009) Plasmacytoid dendritic cells during infancy are inversely associated with childhood respiratory tract infections and wheezing. J Allergy Clin Immunol 124: 707-713 e702.
47. Simon HU, Seelbach H, Ehmann R, Schmitz M, (2003) Clinical and immunological effects of low-dose IFN-alpha treatment in patients with corticosteroid-resistant asthma. Allergy 58: 1250-1255.
48. Cakebread JA, Xu Y, Grainge C, Kehagia V, Howarth PH, et al. (2011) Exogenous IFN-beta has antiviral and anti-inflammatory properties in primary bronchial epithelial cells from asthmatic subjects exposed to rhinovirus. J Allergy Clin Immunol 127: 1148-1154.